Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.

Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ.

Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. No abstract available.

2.

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T.

Mol Ther. 2017 Aug 2;25(8):1946-1958. doi: 10.1016/j.ymthe.2017.04.024. Epub 2017 May 13.

3.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.

4.

Blood and lymphatic microvessel damage in irradiated human skin: The role of TGF-β, endoglin and macrophages.

Russell NS, Floot B, van Werkhoven E, Schriemer M, de Jong-Korlaar R, Woerdeman LA, Stewart FA, Scharpfenecker M.

Radiother Oncol. 2015 Sep;116(3):455-61. doi: 10.1016/j.radonc.2015.08.024. Epub 2015 Sep 4.

PMID:
26347496
5.

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Nijhof IS, Groen RW, Lokhorst HM, van Kessel B, Bloem AC, van Velzen J, de Jong-Korlaar R, Yuan H, Noort WA, Klein SK, Martens AC, Doshi P, Sasser K, Mutis T, van de Donk NW.

Leukemia. 2015 Oct;29(10):2039-49. doi: 10.1038/leu.2015.123. Epub 2015 May 15.

PMID:
25975191
6.

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens AC, Mutis T.

Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.

Supplemental Content

Loading ...
Support Center